- Home
- UUU vs INAB Comparison
UUU vs INAB Comparison
Compare UUU & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UUU | INAB |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5M | 15.6M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UUU | INAB |
|---|---|---|
| Price | $6.25 | $1.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 16.7K | ★ 58.7K |
| Earning Date | 02-19-2026 | 05-11-2026 |
| Dividend Yield | ★ 16.75% | N/A |
| EPS Growth | ★ 229.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $23,563,554.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.39 | N/A |
| 52 Week Low | $2.30 | $0.13 |
| 52 Week High | $8.27 | $4.20 |
Technical Indicators
Market Signals| Indicator | UUU | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 51.91 |
| Support Level | $3.95 | $1.52 |
| Resistance Level | $6.75 | $1.69 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 66.21 | 55.17 |
Price Performance
Historical ComparisonAbout UUU Universal Security Instruments Inc.
Universal Safety Products Inc is a U.S.-based importer and distributor of home safety devices such as ventilation fans and ground fault circuit interrupters.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.